The purpose of this study is to analyze gene expression signature and immunohistochemical markers associated with clinical and pathological response to neoadjuvant chemotherapy in locally advanced breast cancer.
Inclusion Criteria: * Women with locally advanced women breast cancer * Histology: ductal ou lobular invasive histology * Agreement to take part in the study and signature of the informed consent * Clinical condition to receive doxorubicin/cyclophosphamide and paclitaxel * ECOG 0 or I Exclusion Criteria: * Not clinical stage III * Inflammatory breast cancer * Previous treatment * Previous diagnosis of cancer (except basal cell or squamous cell skin carcinoma and non-invasive cervical carcinoma) * Pregnancy * Absence of clinical condition to receive chemotherapy